Research, Collaboration and Licensing Agreements - Additional Information - Strategic Partnership Revenue (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 5,442,000	$ 1,771,000	$ 7,358,000	$ 2,415,000
Contract assets	3,000,000		3,000,000		$ 0
Performance obligation recognized	0	0	0	0
License Option
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue		$ 0	5,000,000	$ 0
Atreca
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, variable consideration option exercise fees and clinical development and regulatory approval milestone payments amount	210,000,000		210,000,000
Revenue, remaining performance obligation, variable consideration commercial milestone payments amount	540,000,000		540,000,000
Atreca | License Option
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	5,000,000
Bei Gene
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue	$ 32,941,000		$ 32,941,000		$ 32,941,000